Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: Pre-operative determination of malignant potential

European Journal of Surgical Oncology

Volumn 24, Issue 1, 1998, Pages 28-33

  Anan, Keisei ^a   Morisaki, Takashi ^a   Katano, Mitsuo ^b   Ikubo, Akashi ^a   Tsukahara, Yasuhiro ^a   Kojima, Masayuki ^a   Uchiyama, Akihiko ^a   Kuroki, Syoji ^a   Torisu, Motomichi ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Prognosis; Reverse transcriptase polymerase chain reaction (RT PCR)

Indexed keywords

CYCLIN D1; HORMONE RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER RECURRENCE; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MESSENGER RNA SYNTHESIS; NEEDLE BIOPSY; ONCOGENE C ERB; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 17144460974     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(98)80121-2     Document Type: Article

References (28)

1. Porter-Jordan K, Lippman ME. Overview of the biologic markers of breast cancer. Hemat Oncol Clin N Am 1994; 8: 73-100.
2. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression; value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995; 221: 706-20.
3. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-7.
4. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995; 1: 1257-60.
5. Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995; 61: 597-600.
6. Galley KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-81.
7. Anan K, Morisaki T, Katano M, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333-9.
8. Ariad S, Seymour L, Bezwoda WR, Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991; 20: 11-7.
9. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
10. May E, Mouriesse H, May-Levin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 1990; 62: 430-5.
11. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-crbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
12. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994; 74: 2956-63.
13. Xiong Y, Connolly T, Fulcher B, Beach D. Human D-type cyclin. Cell 1991; 65: 691-9.
14. Schwartz GK, Wang H, Lampen N, et al. Defining the invasive phenotype of proximal gastric cancer cells. Cancer 1994; 73: 22-7.
15. Betsholtz C, Johnsson A, Heldin CH, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 1986; 320: 695-9.
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
17. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by human c-erbB2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-4.
18. Ponte P, Ng S-Y, Engel J, et al. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucl Acid Res 1984; 12: 1687-96.
19. Chomcyzynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
20. Parums DV, Cordell JL, Micklem K, et al. JC70. A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7.
21. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
23. Lee AK, DeLellis RA, Silverman ML, et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-netative carcinoma of the breast. J Clin Oncol 1990; 8: 1457-65.
24. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-87.
25. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Cancer Res 1996; 56: 2013-6.
26. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77: 1101-6.
27. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 84: 1045-9.
28. Robinson IA, McKee G, Nicholson A, et al. Prognostic value of cytological grading of fine-needle aspirates from breast carcinomas. Lancet 1994; 343: 947-9.